Cargando…
RIPK1 is aberrantly expressed in multiple B-cell cancers and implicated in the underlying pathogenesis
According to the latest epidemiology of the US, B-cell cancers account for > 3% of all new cancer cases and > 80% of non-Hodgkin lymphomas. However, the disease-modifying small molecular drug suitable for most B-cell cancers is still lacking. RIPK1 (receptor-interacting serine/threonine-protei...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353973/ https://www.ncbi.nlm.nih.gov/pubmed/37462822 http://dx.doi.org/10.1007/s12672-023-00725-z |